Search


BioTrinity 2025: AlveoGene Executive Chair David Hipkiss describes the company's unique inhaled gene therapy platform that fuses a Sendai virus and Lentivirus, and can be redosed
He describes the science behind the platform, which is already being used by Boehringer Ingelheim for cystic fibrosis. AlveoGene has...
Apr 1








.png)




